Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol (ADNI3)

What is the purpose of this trial?

Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD. ADNI3 continues the previously funded ADNI-1, ADNI-GO, and ADNI-2 studies that have been combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's disease (AD). The overall goal of the study is to continue to discover, optimize, standardize, and validate clinical trial measures and biomarkers used in AD research.


Participation Guidelines

Ages: 55 - 90 years

Gender: Both


Alzheimer's Therapeutic Research Institute

Dates: 03/28/2017 - 10/31/2021

Last Updated: 06/28/2017

Study HIC#: 1608018296

Get Involved

For more information about this study, contact:
Srinath Ramanan

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image

Investigators

Christopher H Van Dyck

Principal Investigator

Sub-Investigators